European private equity deal-making reached an all-time high in 2018 despite losing some momentum in the final quarter, according to the latest Unquote Private Equity Barometer, published in association with Aberdeen Standard Investments.
New and historical backers invest in Belgium-based Imcyse, a developer of immunotherapies
Ergon uses its Ergon Capital Partners IV vehicle, which closed on €580m in March 2019
Buyout of the baking product company is the GP's fifth UK deal since opening a Manchester office
Sale ends an eight-year holding period for the GP, which owned an 83.4% stake in the company